Industry News
Biotechnology Industry News
From now on, MEI…
From now on, MEI Pharma—previously best known for its clinical-stage leukemia drug—will be called Lite Strategy.
PMV Pharmaceuticals has reported a…
PMV Pharmaceuticals has reported a 43% response rate in a midphase ovarian cancer trial, putting the biotech on a track it believes will lead to a filing for FDA approval in the first quarter of
The Trump administration is…
The Trump administration is considering putting “severe restrictions” on the increasing flow of investigational drugs from China, according to reporting by The New York Times.
Robert Abel of Schrödinger…
Robert Abel of Schrödinger discusses how AI and physics-based modeling are reshaping drug discovery.
Odyssey Therapeutics’ team of…
Odyssey Therapeutics’ team of seasoned drug developers is welcoming another impressive fundraising round, closing a $213 million series D round after abandoning plans to go public this summer.
Protara applies modern science,…
Protara applies modern science, manufacturing, and regulatory expertise to reimagine proven medicines and deliver new treatment options for patients.
Capricor Therapeutics has publicly…
Capricor Therapeutics has publicly released its July response to the FDA's rejection of its Duchenne muscular dystrophy cell therapy deramiocel after the agency included deramiocel in a new batch of complete response letters (CRLs) released
Pfizer veteran Suneet Varma has…
Pfizer veteran Suneet Varma has found his next role. Months after leaving the Big Pharma, Varma has taken the CEO position at the newly created inflammation and immunology startup Intent Biologics.
Eli Lilly is inviting early-stage…
Eli Lilly is inviting early-stage biotechs to make use of drug discovery models that the pharma is providing via a new AI platform.
Novartis is paying $1.4 billion to…
Novartis is paying $1.4 billion to get its hands on Tourmaline Bio and its former Pfizer cardiovascular drug that impressed in a phase 2 study earlier this year.
The CNS-focused company is looking…
The CNS-focused company is looking to pull off the first biotech IPO since February and collect $228.5 million in much-needed funding for further clinical development of its schizophrenia candidate.
After previously delaying its…
After previously delaying its decision date, the FDA has outright rejected Saol Therapeutics’ investigational treatment for an ultra-rare pediatric mitochondrial disease.
Regeneron’s allergen-blocking…
Regeneron’s allergen-blocking antibodies have reduced the symptoms of cat and pollen allergies in a pair of phase 3 studies.
Dianthus Therapeutics is advancing…
Dianthus Therapeutics is advancing its challenge for the increasingly competitive generalized myasthenia gravis (gMG) market, outlining plans to move into phase 3 on the back of hits in a midphase study.
Atom Therapeutics is touting data…
Atom Therapeutics is touting data from a phase 2b/3 study as evidence that its gout drug has the efficacy and safety profile to stand out from the competition.
A phase 2a trial of Rapport…
A phase 2a trial of Rapport Therapeutics’ focal onset seizure drug candidate has hit its primary endpoint, sending shares in the biotech up more than 157% in premarket trading.
Takeda and Alkermes both took data…
Takeda and Alkermes both took data from their orexin receptor 2 (OX2R)-selective agonists to Singapore this morning as the race to get a new class of narcolepsy drug approved heats up.
Junshi has announced that its…
Junshi has announced that its IL-17 antibody hit the goals of a phase 3 psoriasis trial in China, setting up the biopharma to seek national approval.
BioNTech and its new partner…
BioNTech and its new partner Bristol Myers Squibb have trotted out the first global data for their PD-L1xVEGF bispecific in small cell lung cancer. BioNTech’s chief medical officer, Özlem Türeci, M.D., described the findings as
Servier is souping up its…
Servier is souping up its neurology pipeline with a clinical-stage candidate for a rare genetic disease sourced from U.K. biotech Kaerus Bioscience. The French pharma is offering as much as $450 million for KER-0193, a